Charles Newton
Direttore Finanziario/CFO presso LYELL IMMUNOPHARMA, INC.
Patrimonio netto: 119 883 $ in data 31/05/2024
Posizioni attive di Charles Newton
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| LYELL IMMUNOPHARMA, INC. | Direttore Finanziario/CFO | 01/02/2021 | - |
| COHERUS BIOSCIENCES, INC. | Direttore/Membro del Consiglio | 05/05/2022 | - |
| Independent Dir/Board Member | 05/05/2022 | - | |
| 2SEVENTY BIO, INC. | Direttore/Membro del Consiglio | 20/03/2024 | - |
| Independent Dir/Board Member | 20/03/2024 | - |
Storia della carriera di Charles Newton
Precedenti posizioni note di Charles Newton
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Carmot Therapeutics, Inc.
 Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | Direttore/Membro del Consiglio | 19/07/2023 | 01/01/2024 |
| Independent Dir/Board Member | 19/07/2023 | 01/01/2024 | |
Credit Suisse Group AG /US/
 Credit Suisse Group AG /US/ Financial ConglomeratesFinance Credit Suisse Group AG /US/ engages in the provision of financial solutions. It offers services for private banking, investment banking, and asset management. The company is headquartered in New York, NY. | Amministratore Delegato | 01/09/2010 | 01/11/2015 |
| MORGAN STANLEY | Corporate Officer/Principal | 01/06/1996 | 01/09/2010 |
BofA Securities, Inc.
 BofA Securities, Inc. Investment Banks/BrokersFinance BofA Securities, Inc. is a registered broker-dealer subsidiary of NB Holdings Corp., ultimately held by Bank of America Corp. (NYSE: BAC). Headquartered in New York, the firm was founded in 2015 and offers trade execution, trading or brokerage services to institutional clients. | Corporate Officer/Principal | - | - |
Formazione di Charles Newton
| Tuck School of Business at Dartmouth | Masters Business Admin |
| Miami University | Undergraduate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 10 |
Posizioni
| Director/Board Member | 3 |
| Independent Dir/Board Member | 3 |
| Corporate Officer/Principal | 2 |
Settori
| Health Technology | 5 |
| Finance | 4 |
| Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 4 |
|---|---|
| LYELL IMMUNOPHARMA, INC. | Health Technology |
| COHERUS BIOSCIENCES, INC. | Health Technology |
| MORGAN STANLEY | Finance |
| 2SEVENTY BIO, INC. | Health Technology |
| Aziende private | 3 |
|---|---|
Credit Suisse Group AG /US/
Credit Suisse Group AG /US/ Financial ConglomeratesFinance Credit Suisse Group AG /US/ engages in the provision of financial solutions. It offers services for private banking, investment banking, and asset management. The company is headquartered in New York, NY. | Finance |
BofA Securities, Inc.
BofA Securities, Inc. Investment Banks/BrokersFinance BofA Securities, Inc. is a registered broker-dealer subsidiary of NB Holdings Corp., ultimately held by Bank of America Corp. (NYSE: BAC). Headquartered in New York, the firm was founded in 2015 and offers trade execution, trading or brokerage services to institutional clients. | Finance |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | Health Technology |
- Borsa valori
- Insiders
- Charles Newton
- Esperienza
